Pneumococcal

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

Pneumococcal conjugate vaccines significantly reduce pneumonia incidence in children, but safety concerns warrant further investigation in future studies.

PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.

At the NCPA 2025 Annual Convention & Expo, Jeannie Grubbs, PharmD, manager at Publix Pharmacy, presented on the reasons why pneumococcal vaccine development is an ongoing process.

Researchers investigate which pneumococcal strains were most responsible for invasive infections among children in Poland.

With emerging vaccines causing a decrease in community-acquired bacterial meningitis, researchers investigated how the prominence in disease pathogens has evolved over 15 years in Korea.

With uncertainty in dosing recommendations, researchers aim to assess the efficacy of pneumococcal conjugate vaccines for the pediatric population.

Significant patient reports show a lack of response to treatment for community-acquired pneumonia, leading researchers to investigate the use of corticosteroids.

The study results highlight the importance of pneumococcal vaccination for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

Using the Vaccine Adverse Event Reporting System database, researchers address adverse events following pneumococcal vaccination, as well as the association between adverse events and vaccine administration.

Merck’s pneumococcal 21-valent conjugate vaccine was noninferior to the pneumococcal 23-valent polysaccharide vaccine for all 12 shared serotypes and superior to 9 unique serotypes.

Due to an increased risk of vaccine-preventable diseases, researchers explore pneumococcal, COVID-19, and influenza vaccine coverage among people living with HIV in Belgium.

Exploring the influences of pneumococcal disease mortality and events of the COVID-19 pandemic, researchers investigate changes in US pneumococcus survival rates since 2020.

Researchers explored the impact of PCV10 on the distribution of invasive pneumococcal disease serotypes among patients in Lithuania.

Simultaneous vaccination with IIV4 and PPSV23 proves safe and effective for patients with chronic diseases, matching results of healthy individuals.

Investigators find a large burden of hospitalization due to community-acquired pneumonia (CAP) for adults in the US, mainly caused by Streptococcus pneumoniae.

Among rural community pharmacies in the US, researchers explored pneumococcal immunization services, the processes used to identify patient eligibility, and the barriers to vaccine administration.

Among pediatric patients in Colombia, researchers explored the prevalence of bacterial acute otitis media caused by Streptococcus pneumoniae.

New research findings reveal amoxicillin's effectiveness varies in treating invasive pneumococcal disease, highlighting the importance of patient-specific factors in antibiotic therapy.

Older adults are more likely to have chronic diseases, such as lung or heart disease, which makes them more susceptible to invasive pneumococcal disease.

Researchers conducted a retrospective cohort study to understand pneumococcal disease patterns, vaccine coverage, and the overall burden of the disease in adults in France.

Recent data highlight the importance of implementing strategies to improve vaccine uptake.